$BTCY
BIOTRICITY INC. Stock $btcy

$btcy Overview Financials Valuation SEC Filings Company Website

2022 Form 10-K Financial Statement

#000149315222019256 Filed on July 14, 2022

Income Statement

Concept	2022	2021 Q1	2021
Revenue	$7.650M	$1.187M	$3.385M
YoY Change	126.02%	227.08%	138.75%
Cost Of Revenue	$3.080M	$468.3K	$2.112M
YoY Change	45.84%	-22.58%	126.63%
Gross Profit	$4.570M	$718.7K	$1.273M
YoY Change	259.08%	-397.05%	162.0%
Gross Profit Margin	59.74%	60.55%	37.6%
Selling, General & Admin	$19.30M	$3.086M	$12.08M
YoY Change	59.8%	-17.94%	20.13%
% of Gross Profit	422.28%	429.4%	948.92%
Research & Development	$2.745M	$551.5K	$2.059M
YoY Change	33.29%	14.05%	51.05%
% of Gross Profit	60.05%	76.73%	161.79%
Depreciation & Amortization	$2.308K		$0.00
YoY Change
% of Gross Profit	0.05%		0.0%
Operating Expenses	$22.59M	$3.638M	$14.62M
YoY Change	54.47%	-14.3%	28.1%
Operating Profit	-$18.02M	-$2.919M	-$13.35M
YoY Change	34.97%	-34.94%	22.15%
Interest Expense	$379.5K	-$2.086M	-$2.969M
YoY Change	-112.78%	3042.84%	3112.89%
% of Operating Profit
Other Income/Expense, Net	$15.12K	-$363.3K	$36.64K
YoY Change	-58.73%	701.08%	-183.57%
Pretax Income	-$29.13M	-$5.472M	-$15.49M
YoY Change	88.05%	18.99%	39.98%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$29.13M	-$5.472M	-$15.49M
YoY Change	88.05%	18.99%	39.98%
Net Earnings / Revenue	-380.78%	-460.94%	-457.67%
Basic Earnings Per Share	-$0.67		-$0.44
Diluted Earnings Per Share	-$640.9K	-$140.4K	-$412.8K
COMMON SHARES
Basic Shares Outstanding	45.45M shares		37.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022	2021 Q1	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.07M	$2.202M	$2.202M
YoY Change	448.11%	131.78%	131.78%
Cash & Equivalents		$2.202M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$842.9K	$272.5K	$272.5K
Prepaid Expenses
Receivables	$2.007M	$1.521M	$1.521M
Other Receivables	$406.3K	$326.7K	$326.7K
Total Short-Term Assets	$15.32M	$4.322M	$4.322M
YoY Change	254.57%	160.52%	160.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.270M		$66.12K
YoY Change	1820.99%		-75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.355M	$116.5K	$116.5K
YoY Change	1063.53%	-66.3%	-66.3%
TOTAL ASSETS
Total Short-Term Assets	$15.32M	$4.322M	$4.322M
Total Long-Term Assets	$1.355M	$116.5K	$116.5K
Total Assets	$16.68M	$4.438M	$4.438M
YoY Change	275.8%	121.41%	121.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.159M	$1.041M	$1.041M
YoY Change	11.34%	-4.82%	-4.82%
Accrued Expenses	$1.647M	$1.479M	$1.537M
YoY Change	7.13%	130.82%	139.91%
Deferred Revenue
YoY Change
Short-Term Debt	$1.540M	$4.278M	$4.278M
YoY Change	-64.0%	106.84%	106.84%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.867M	$10.49M	$10.49M
YoY Change	-53.61%	175.84%	175.84%
LONG-TERM LIABILITIES
Long-Term Debt	$12.48M	$370.9K	$370.9K
YoY Change	3265.72%
Other Long-Term Liabilities	$1.472M	$410.0K	$410.0K
YoY Change	259.09%	-65.88%	-65.88%
Total Long-Term Liabilities	$13.96M	$780.9K	$780.9K
YoY Change	1687.06%	-35.02%	-35.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.867M	$10.49M	$10.49M
Total Long-Term Liabilities	$13.96M	$780.9K	$780.9K
Total Liabilities	$18.82M	$11.27M	$11.27M
YoY Change	67.0%	125.21%	125.21%
SHAREHOLDERS EQUITY
Retained Earnings		-$62.82M
YoY Change
Common Stock		$39.02K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.145M	-$6.833M	-$6.833M
YoY Change
Total Liabilities & Shareholders Equity	$16.68M	$4.438M	$4.438M
YoY Change	275.8%	121.41%	121.41%

Cashflow Statement

Concept	2022	2021 Q1	2021
OPERATING ACTIVITIES
Net Income	-$29.13M	-$5.472M	-$15.49M
YoY Change	88.05%	18.99%	39.98%
Depreciation, Depletion And Amortization	$2.308K		$0.00
YoY Change
Cash From Operating Activities	-$15.16M	-$3.580M	-$11.08M
YoY Change	36.84%	21.23%	40.93%
INVESTING ACTIVITIES
Capital Expenditures	$29.77K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$29.77K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$250.0K		$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$25.17M	2.586M	$12.20M
YoY Change	106.24%	-541.71%	37.44%
NET CHANGE
Cash From Operating Activities	-$15.16M	-3.580M	-$11.08M
Cash From Investing Activities	-$29.77K
Cash From Financing Activities	$25.17M	2.586M	$12.20M
Net Change In Cash	$9.975M	-993.4K	$1.123M
YoY Change	788.53%	-71.93%	10.45%
FREE CASH FLOW
Cash From Operating Activities	-$15.16M	-$3.580M	-$11.08M
Capital Expenditures	$29.77K
Free Cash Flow	-$15.19M		-$11.08M
YoY Change	37.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7650269	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3384767	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4866814	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001630113
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent		usd
CY2022Q1	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent		usd
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2021Q1	us-gaap	Long Term Loans From Bank LongTermLoansFromBank		usd
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021	us-gaap	Depreciation Depreciation		usd
CY2021	BTCY	Lease Expenses LeaseExpenses		usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	BTCY	Proceeds From Issuance Of Shares From Uplisting ProceedsFromIssuanceOfSharesFromUplisting		usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross		usd
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		usd
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-56074
CY2022	dei	Entity Registrant Name EntityRegistrantName	BIOTRICITY INC.
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29767	usd
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2022	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001
CY2022	dei	City Area Code CityAreaCode	(650)
CY2022	dei	Local Phone Number LocalPhoneNumber	832-1626
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0983531
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	275 Shoreline Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
CY2022	dei	Trading Symbol TradingSymbol	BTCY
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Public Float EntityPublicFloat	114849788	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50301806	shares
CY2022	dei	Auditor Firm AuditorFirmId	5828
CY2022	dei	Auditor Name AuditorName	SRCO Professional Corporation
CY2022	dei	Auditor Location AuditorLocation	Richmond Hill, Ontario, Canada
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12066929	usd
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2201562	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2006678	usd
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1520836	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	842924	usd
CY2021Q1	us-gaap	Inventory Net InventoryNet	272493	usd
CY2022Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	406280	usd
CY2021Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	326664	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	15322811	usd
CY2021Q1	us-gaap	Assets Current AssetsCurrent	4321555	usd
CY2022Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	85000	usd
CY2021Q1	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	50358	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27459	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1242700	usd
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	66120	usd
CY2022Q1	us-gaap	Assets Assets	16677970	usd
CY2021Q1	us-gaap	Assets Assets	4438033	usd
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2595747	usd
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2520124	usd
CY2022Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1540000	usd
CY2021Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4278018	usd
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	520747	usd
CY2021Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3633856	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	210320	usd
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	58257	usd
CY2021Q1	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	370900	usd
CY2022Q1	BTCY	Derivative Loss Accretion Expense DerivativeLossAccretionExpense	401986	usd
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10490255	usd
CY2022Q1	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	870800	usd
CY2022Q1	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	11612672	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	352402	usd
CY2021Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	410042	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1120018	usd
CY2022Q1	us-gaap	Liabilities Liabilities	18822706	usd
CY2021Q1	us-gaap	Liabilities Liabilities	11271197	usd
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49810322	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49810322	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36124964	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36124964	shares
CY2022Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2021Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	2889978	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	51277	usd
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	39015	usd
CY2022Q1	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	123817	shares
CY2021Q1	BTCY	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	268402	shares
CY2022Q1	BTCY	Shares To Be Issued SharesToBeIssued	102299	usd
CY2021Q1	BTCY	Shares To Be Issued SharesToBeIssued	280960	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	91507478	usd
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56298726	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-768656	usd
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-634186	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93037142	usd
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62817688	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-6833164	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16677970	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15163384	usd
CY2021	BTCY	Loss Upon Convertible Promissory Notes Conversion LossUponConvertiblePromissoryNotesConversion	103735	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9286023	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2481155	usd
CY2022	BTCY	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	976242	usd
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4438033	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-683559	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	408872	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3080116	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	2112035	usd
CY2022	us-gaap	Gross Profit GrossProfit	4570153	usd
CY2021	us-gaap	Gross Profit GrossProfit	1272732	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19845939	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12565396	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2744587	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2059130	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	22590526	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	14624526	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15120	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36636	usd
CY2022	BTCY	Loss Upon Convertible Promissory Notes Conversion LossUponConvertiblePromissoryNotesConversion	1155642	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29130477	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15491176	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29130477	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15491176	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1088977	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	962148	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30219454	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16453324	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-134470	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	223121	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30353924	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16230203	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.665
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.438
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45449720	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37522978	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-6833164	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	250000	usd
CY2022	BTCY	Issuance Of Preferred Shares For Private Placement Investors IssuanceOfPreferredSharesForPrivatePlacementInvestors	100000	usd
CY2022	BTCY	Adjustment To Additional Paid In Capital Derivative Liabilities Adjustment Pursuant To Issuance Of Preferred Shares AdjustmentToAdditionalPaidInCapitalDerivativeLiabilitiesAdjustmentPursuantToIssuanceOfPreferredShares	-17084	usd
CY2022	BTCY	Issuance Of Shares From Uplisting IssuanceOfSharesFromUplisting	14545805	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	15678454	usd
CY2022	BTCY	Conversion Of Preferred Shares Into Common Shares ConversionOfPreferredSharesIntoCommonShares	633805	usd
CY2022	BTCY	Preferred Stock Purchased Back Via Cash PreferredStockPurchasedBackViaCash	-193448	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1414449	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15491176	usd
CY2021	BTCY	Preferred Stock Dividends PreferredStockDividends	962148	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	60665	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	156590	usd
CY2022	BTCY	Adjustments To Additional Paid In Capital Issuancof Warrants For Services AdjustmentsToAdditionalPaidInCapitalIssuancofWarrantsForServices	740156	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	913613	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-6833164	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	948997	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	752353	usd
CY2022	BTCY	Cashless Exercise Of Warrants Value CashlessExerciseOfWarrantsValue	360	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-134470	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29130477	usd
CY2022	BTCY	Preferred Stock Dividends PreferredStockDividends	1088977	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2144736	usd
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-3000393	usd
CY2021	BTCY	Issuance Of Preferred Shares For Private Placement Investors IssuanceOfPreferredSharesForPrivatePlacementInvestors	215000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5758572	usd
CY2021	BTCY	Issuance Costs Warrants To Brokers IssuanceCostsWarrantsToBrokers	1258878	usd
CY2021	BTCY	Adjustment To Additional Paid In Capital Derivative Liabilities Adjustment Pursuant To Issuance Of Preferred Shares AdjustmentToAdditionalPaidInCapitalDerivativeLiabilitiesAdjustmentPursuantToIssuanceOfPreferredShares	-41749	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1076561	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2598863	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	740772	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	790535	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	223121	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-29130477	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-15491176	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	913613	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	790535	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1414449	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2530922	usd
CY2022	BTCY	Issuance Of Warrants For Services At Fair Value IssuanceOfWarrantsForServicesAtFairValue	541443	usd
CY2021	BTCY	Issuance Of Warrants For Services At Fair Value IssuanceOfWarrantsForServicesAtFairValue	740772	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	9286023	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	2481155	usd
CY2022	BTCY	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-683559	usd
CY2021	BTCY	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	408872	usd
CY2022	BTCY	Loss On Debt Conversion LossOnDebtConversion	1155642	usd
CY2021	BTCY	Loss On Debt Conversion LossOnDebtConversion	103735	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1200000	usd
CY2022	us-gaap	Depreciation Depreciation	2308	usd
CY2022	BTCY	Lease Expenses LeaseExpenses	87639	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	435484	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1036892	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	570431	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	186773	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11080831	usd
CY2021	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	602969	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25168230	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29767	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	250000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	100000	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	200000	usd
CY2022	us-gaap	Payments For Repurchase Of Redeemable Preferred Stock PaymentsForRepurchaseOfRedeemablePreferredStock	230000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	872292	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	67941	usd
CY2022	BTCY	Federal Guaranteed Loans FederalGuaranteedLoans	499900	usd
CY2021	BTCY	Federal Guaranteed Loans FederalGuaranteedLoans	1570900	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	11375690	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-1660220	usd
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-408082	usd
CY2022	BTCY	Proceeds From Issuance Of Shares From Uplisting ProceedsFromIssuanceOfSharesFromUplisting	14545805	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	11756563	usd
CY2022	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	966110	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12203480	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-109712	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	129065	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9975079	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1122649	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2201562	usd
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	949848	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12066929	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2201562	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	553265	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	204161	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zsePN8hk9RF4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_826_z6e5XGAVeq29">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over, which took place on February 2, 2016.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93037142	usd
CY2022Q1	BTCY	Working Capital Deficit WorkingCapitalDeficit	10455997	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14545805	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11756563	usd
CY2022	us-gaap	Revenue Recognition Leases Operating RevenueRecognitionLeasesOperating	<p id="xdx_84F_eus-gaap--RevenueRecognitionLeasesOperating_zgDpU7cdhqra" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86F_zdzM3nR5QJIj">Revenue Recognition</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted Accounting Standards Codification Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) on April 1, 2018. In accordance with ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services by applying the core principles – 1) identify the contract with a customer, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to performance obligations in the contract, and 5) recognize revenue as performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Bioflux mobile cardiac telemetry device, a wearable device, is worn by patients for a monitoring period up to 30 days. The cardiac data that the device monitors and collects is curated and analyzed by the Company’s proprietary algorithms and then securely communicated to a remote monitoring facility for electronic reporting and conveyance to the patient’s prescribing physician or other certified cardiac medical professional. Revenues earned with respect to this device are comprised of device sales revenues and technology fee revenues (technology as a service). The device, together with its licensed software, is available for sale to the medical center or physician, who is responsible for the delivery of clinical diagnosis and therapy. The remote monitoring, data collection and reporting services performed by the technology culminate in a patient study that is generally billable when it is complete and is issued to the physician. In order to recognize revenue, management considers whether or not the following criteria are met: persuasive evidence of a commercial arrangement exists, and delivery has occurred or services have been rendered. For sales of devices, which are invoiced directly, additional revenue recognition criteria include that the price is fixed and determinable and collectability is reasonably assured; for device sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income; for revenue that is earned based on customer usage of the proprietary software to render a patient’s cardiac study, the Company recognizes revenue when the study ends based on a fixed billing rate. Costs associated with providing the services are recorded as the service is provided regardless of whether or when revenue is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may also earn service-related revenue from contracts with other counterparties with which it consults. This contract work is separate and distinct from services provided to clinical customers, but may be with a reseller or other counterparties that are working to establish their operations in foreign jurisdictions or ancillary products or market segments in which the Company has expertise and may eventually conduct business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_zcgyKW7R57cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized the following forms of revenue for the fiscal years ended March 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zr8f00IDEm37" style="display: none">SCHEDULE OF REVENUE RECOGNITION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210401__20220331_zv64qIA8JzH7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20200401__20210331_zPVEorcuN4c2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--DeviceSalesMember_zLkctTeTLJg6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Device sales</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 16%; font-weight: bold; text-align: right">995,876</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 16%; font-weight: bold; text-align: right">635,901</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--TechnologyFeesMember_zxfe8czN8Y01" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Technology fees</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">5,904,393</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">2,748,866</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--ServiceRelatedAndOtherRevenueMember_z5D2fDCwCzSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Service-related and other revenue</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zrR56lnczjij" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> <span style="display: none; font-family: Times New Roman, Times, Serif">Revenue</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,650,269</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,384,767</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/><p id="xdx_8A5_zpIVhTiDDOlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2022Q1	BTCY	Convertible Promissory Notes And Short Term Loans ConvertiblePromissoryNotesAndShortTermLoans	1540000	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12000000	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-21
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	144953	usd
CY2021Q4	us-gaap	Business Exit Costs1 BusinessExitCosts1	12000000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7650269	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3384767	usd
CY2021Q4	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1574068	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2021Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	501200	usd
CY2021Q2	BTCY	Derivative Loss Accretion Expense DerivativeLossAccretionExpense	2335167	usd
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1042149	usd
CY2021Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1157500	usd
CY2021Q2	BTCY	Convertible Promissory Notes And Short Term Loans ConvertiblePromissoryNotesAndShortTermLoans	3795465	usd
CY2022Q1	BTCY	Accretion Of Debt Discount AccretionOfDebtDiscount	353588	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	54822	usd
CY2022Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1159477	usd
CY2021Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	1041385	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1436270	usd
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1478739	usd
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2595747	usd
CY2021Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2520124	usd
CY2022Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2851	usd
CY2021Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	182995	usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	151797	usd
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.06
CY2021Q1	BTCY	Convertible Promissory Notes And Short Term Loans ConvertiblePromissoryNotesAndShortTermLoans	2617798	usd
CY2021Q2	BTCY	Accretion Of Debt Discount AccretionOfDebtDiscount	1833967	usd
CY2021Q3	BTCY	Accretion Of Debt Discount AccretionOfDebtDiscount	4627415	usd
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	537304	usd
CY2021Q3	BTCY	Derivative Loss Accretion Expense DerivativeLossAccretionExpense	5164719	usd
CY2021Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	8679000	usd
CY2021Q3	BTCY	Convertible Promissory Notes And Short Term Loans ConvertiblePromissoryNotesAndShortTermLoans	281184	usd
CY2021Q4	BTCY	Accretion Of Debt Discount AccretionOfDebtDiscount	782726	usd
CY2021Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	546604	usd
CY2021Q4	BTCY	Derivative Loss Accretion Expense DerivativeLossAccretionExpense	1329330	usd
CY2021Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	472500	usd
CY2021Q4	BTCY	Convertible Promissory Notes And Short Term Loans ConvertiblePromissoryNotesAndShortTermLoans	1138014	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	57536	shares
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	48398	usd
CY2021Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	198713	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	50000	usd
CY2021Q4	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	on each February
CY2021Q4	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	193437	usd
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	48484	usd
CY2021Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	410042	usd
CY2021Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	121828	usd
CY2021Q4	BTCY	Reduction Due To Preferred Shares Redeemed Or Converted ReductionDueToPreferredSharesRedeemedOrConverted	-472835	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-644774	usd
CY2021Q4	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2022-02-15
CY2021Q4	us-gaap	Debt Instrument Payment Terms DebtInstrumentPaymentTerms	Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. Prepayment of amounts owing under the Credit Agreement are allowed under prescribed circumstances
CY2021Q4	BTCY	Origination Fee Amount OriginationFeeAmount	120000	usd
CY2021Q4	BTCY	Exit Fees ExitFees	600000	usd
CY2022	us-gaap	Interest Expense InterestExpense	379500	usd
CY2022	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	153974	usd
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	203525	usd
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	206517	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	17084	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	101773	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	7146572	shares
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	293767	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-58635	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	10843202	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	449174	shares
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	352402	usd
CY2021Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3633856	usd
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49810322	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36124964	shares
CY2022Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1466718	shares
CY2021Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	2889978	shares
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	1900042	shares
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	250000	shares
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1414449	usd
CY2022Q1	us-gaap	Shares Outstanding SharesOutstanding	123817	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	97500	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	658355	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	97500	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	446370	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5396723	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	148750	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1021430	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6269403	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	2475273	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	97500	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1459918	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	643534	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9577644	shares
CY2021Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	41256	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11231073	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
CY2021Q1	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	7311800	usd
CY2022Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16283	usd
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.76
CY2022	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2021	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2020	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.26	pure
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29130477	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15491176	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-7573924	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-4027706	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3645962	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1313530	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-24972	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-38579	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3952934	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2752755	usd
CY2022Q1	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	11214790	usd
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7353056	usd
CY2022Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	43133807	usd
CY2021Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	28122308	usd
CY2022	BTCY	Operating Loss Carryforwards Expiration Date Description OperatingLossCarryforwardsExpirationDateDescription	These losses will expire between 2035 to 2039
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114	pure
CY2021Q1	BTCY	Operating Lease Right Of Use Asset Initial Recognition OperatingLeaseRightOfUseAssetInitialRecognition	1308731	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	66031	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1242700	usd
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1308730	usd
CY2022	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	21608	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1330338	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	210320	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1120018	usd
CY2022	BTCY	Schedule Of Contractual Undiscounted Cashflows For Lease Obligation Table Textblock ScheduleOfContractualUndiscountedCashflowsForLeaseObligationTableTextblock	<p id="xdx_89F_ecustom--ScheduleOfContractualUndiscountedCashflowsForLeaseObligationTableTextblock_z2xvQNKAICEa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zpjuH93dwZc2" style="display: none">SCHEDULE OF CONTRACTUAL UNDISCOUNTED CASH FLOWS FOR LEASE OBLIGATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Less than one year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20220331__us-gaap--LeaseContractualTermAxis__custom--LessThanOneYearMember_pp0p0" style="width: 18%; text-align: right" title="Total undiscounted lease obligations">348,565</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Beyond one year</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20220331__us-gaap--LeaseContractualTermAxis__custom--BeyondOneYearMember_pdp0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total undiscounted lease obligations">1,368,654</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total undiscounted lease obligations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c20220331_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total undiscounted lease obligations">1,717,219</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1717219	usd
CY2022Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	12928	usd
CY2022Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	16839	usd
CY2022	us-gaap	Depreciation Depreciation	2308	usd
CY2022	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	29767	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2022	us-gaap	Depreciation Depreciation	2308	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2308	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27459	usd
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	60000	shares

Files In Submission

Name	View Source	Status
0001493152-22-019256-index-headers.html	Edgar Link	pending
0001493152-22-019256-index.html	Edgar Link	pending
0001493152-22-019256.txt	Edgar Link	pending
0001493152-22-019256-xbrl.zip	Edgar Link	pending
btcy-20220331.xsd	Edgar Link	pending
btcy-20220331_cal.xml	Edgar Link	unprocessable
btcy-20220331_def.xml	Edgar Link	unprocessable
btcy-20220331_lab.xml	Edgar Link	unprocessable
btcy-20220331_pre.xml	Edgar Link	unprocessable
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex99-1.htm	Edgar Link	pending
ex99-2.htm	Edgar Link	pending
ex99-3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTCY
BIOTRICITY INC. Stock $btcy

2022 Form 10-K Financial Statement

#000149315222019256 Filed on July 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY BIOTRICITY INC. Stock $btcy

2022 Form 10-K Financial Statement

#000149315222019256 Filed on July 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY
BIOTRICITY INC. Stock $btcy